Because the prices of U.S.-listed Chinese stocks plunged lately due to China’s crackdown on its tech and education sectors, some of these stocks could be solid bargains now considering their long-term growth potential.

After a strong session overnight, ASHR has risen almost 4% today for its best single-day performance since July 6th of last year when the ETF popped 11.24%.

After surging to 52-week highs at the very end of 2020 and into the new year, the Xtrackers CSI 300 ETF (ASHR​​​​​​​) tracking China A-Shares collapsed back below its 50-DMA.

The 2020 market year is officially behind us, and for most of the ETFs in our Asset Class Performance Matrix it was a great year. The top-performing ETF in our matrix was the Nasdaq 100. Fittingly, in second place silver posted a gain of 47.5%.

The US-China trade war continues to be stuck in the mud with comments today by the two countries’ presidents being a prime example of the back and forth banter that has been the case for the past year and a half.

One of the biggest stories in the financial markets today is the White House contemplating limiting or completely choking off investment into China.

Here is a look at a sector and asset class ETF chart and it seems many market participants have been leaning heavily against the China “trade war” trade this year.

The financial system is in trouble. Indeed, by the look of things, we are about to experience a wave of deflation… in years.

The ASHR​ ETF (which tracks large-cap onshore Chinese stocks) has gotten badly oversold.

After multiple rounds of negotiation this year, the United States and China have finally declared an all-out trade war that has shaken up the latter’s financial markets.

S&P500 valuations were on the high side in early January, but a reset has since occurred. Not cheap, but not expensive either.

Emerging markets have been off to the races in 2017 and China has played a huge role in fueling that growth.

Biotechs are fairly volatile on a short-term basis but still represent one of the better long-term growth plays. With a P/E ratio of 22, the Biotech ETF (IBB) isn’t unreasonably expensive and may yet have more room to run.

The U.S. index provider MSCI announced its long-awaited decision to include China-A shares to its global equity index and the emerging market index, beginning June 2018.

The PBOC has been guiding money market rates higher since to close the offshore/onshore yield differential with Hong Kong, discourage capital outflows and maintain stability with the yuan as the HKMA raises rates.

A few charts on a few trade setups that I’m focused and may provide a trade or two over the coming sessions.